ENvue Medical's Third Reverse Split Since 2025 Takes Effect Under a Nasdaq Delisting Determination

by Jonas Halvorsen · September 1, 2026

Companies Reporter, The MicroCap Herald

ENvue Medical, Inc. (Nasdaq: FEED) put a 1-for-12 reverse stock split into effect on Tuesday, September 1, the third such consolidation the enteral-care device company has carried out since early 2025. According to the company's August 28 announcement, the split reduces shares outstanding from 11,084,616 to approximately 923,718. Authorized shares remain at 40,000,000 and par value remains $0.001. The stock continues to trade under the symbol FEED with a new CUSIP number, 63008J876, and VStock Transfer, LLC is acting as exchange agent. No fractional shares are being issued; the announcement states that any resulting fractional shares are rounded up to the nearest whole share on a per-stockholder basis.

The board set the ratio under authority granted by stockholders at a special meeting held August 14, 2026. The August 28 announcement itself does not state a reason for the split. The reason appears in the proxy statement that solicited the vote.

That definitive proxy discloses that ENvue received a staff determination letter from Nasdaq's Listing Qualifications Department on July 10, 2026, after its closing bid price sat below $1.00 for the 30 consecutive business days running from May 26 through July 8, 2026 — a breach of Nasdaq Listing Rule 5550(a)(2). The proxy asked shareholders to authorize a reverse split within a range of 1-for-2 to 1-for-50, leaving the board to select the ratio.

The more consequential disclosure in that document concerns what ENvue was not offered. Companies that fall below the $1.00 mark normally get an automatic 180-calendar-day period to cure. ENvue did not. The proxy states that the company is not eligible for any compliance period specified in Nasdaq Listing Rule 5810(c)(3)(A) because it effected a reverse stock split over the prior one-year period, citing Rule 5810(c)(3)(A)(iv). ENvue has carried out two prior consolidations — a 1-for-11 on March 13, 2025 and a 1-for-10 on August 12, 2025 — but only the August 2025 split fell inside the one-year window preceding the July 2026 letter, and one is enough: the rule is triggered by a single split in the prior year rather than by a cumulative count. The proxy states the company intends to request a hearing before a Nasdaq panel, and that a timely request for a hearing will stay any suspension or delisting action pending the panel's decision.

The company's own risk language in that filing is unambiguous: there can be no assurance that the request for continued listing will be granted, or that ENvue will regain and maintain compliance with the minimum bid price requirement or the other continued-listing standards. Taken together, the three ratios compound to roughly 1,320 pre-March-2025 shares for every share held after Tuesday's consolidation.

A note on the age of the numbers that follow: ENvue's most recent financial statements cover the six months ended June 30, 2026 and were filed on August 17. They are more than two months old, and they predate both the August equity financing arrangements and Tuesday's split. Readers should treat them accordingly.

In that quarterly report, ENvue disclosed revenue of $892,000 for the first half of 2026, down from $1,519,000 in the comparable 2025 period, and a net loss of $8,721,000 for the six months. Cash stood at $1,084,000 at June 30, against $4,224,000 at December 31, 2025. Accumulated deficit was $124,448,000. Current assets of $4,818,000 against current liabilities of $7,305,000 produced a working capital deficit of roughly $2,487,000. Current liabilities included a $1,080,000 loan and an accrued arbitration liability of $2,319,000. The filing states that these conditions raise substantial doubt about the company's ability to continue as a going concern.

Share issuance ran well ahead of the balance-sheet date. The company reported 8,194,387 common shares outstanding at June 30, 2026 and 11,084,615 as of August 17 — an increase of roughly 35 percent in seven weeks, before any of the August financing capacity was drawn.

That capacity is substantial. In an August 12 current report, ENvue disclosed a committed equity facility of up to $50.0 million with an institutional investor. Shares sold under the facility are priced at 90 percent of the lowest volume-weighted average price over a three-trading-day measurement window. The facility runs 36 months from commencement, which does not occur until a resale registration statement is declared effective and a final prospectus is filed. Forty percent of net proceeds must be applied to redeem Series X preferred stock; the balance is earmarked for working capital. The company may terminate on five trading days' notice after commencement.

The same filing expanded additional investment rights attached to the Series H preferred stock to $59.0 million in stated value, or 59,000 shares, with a subscription amount of $53.1 million. The amendment requires shareholder approval to take effect. Once that approval is obtained, a minimum of $10.0 million must be exercised over the following twelve months, with a monthly minimum of $833,333.33; that minimum decreases dollar-for-dollar upon specified fundraising events.

The structural point for holders is straightforward and worth stating plainly: an equity line priced at a discount to a trailing low price issues more shares as the share price falls, and a reverse split changes the number of shares outstanding without changing the value of the company behind them. Neither the facility nor the split addresses the operating cash burn the June quarter disclosed.

ENvue is headquartered in Tyler, Texas, with research and development in Tel Aviv, Israel and Arlington Heights, Illinois. The company describes its ENvue Navigation Platform as a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes; the release states it is FDA 510(k) cleared for adult use, and that future platform expansion may include pediatric and vascular access applications. Its PainShield and UroShield products use what the company calls proprietary low-intensity surface acoustic wave technology.

Trading Tuesday was the first session on the new share count, and the US market remained open at the time of writing, so no closing print is available. Investing.com reported that the stock opened at $4.42 on a split-adjusted basis and drifted to $4.14, with a session low of $4.05 and a 52-week low of $3.48, all on a split-adjusted basis. The Herald does not report intraday levels as settled figures.

The near-term items on the calendar are the outcome of the Nasdaq panel hearing, the effectiveness of the resale registration statement that would let the equity facility commence, and a shareholder vote on the Series H amendment. None of the three is assured, and the company has said as much in its own filings.